Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02JCM
|
||||
| Former ID |
DIB020463
|
||||
| Drug Name |
N(6)-cyclohexyladenosine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H23N5O4
|
||||
| InChI |
InChI=1S/C16H23N5O4/c22-6-10-12(23)13(24)16(25-10)21-8-19-11-14(17-7-18-15(11)21)20-9-4-2-1-3-5-9/h7-10,12-13,16,22-24H,1-6H2,(H,17,18,20)/t10-,12-,13-,16-/m1/s1
|
||||
| InChIKey |
SZBULDQSDUXAPJ-XNIJJKJLSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
14802819, 17404894, 24139429, 26753545, 44939362, 47574445, 47574446, 47574447, 47721688, 47796119, 47870803, 48095612, 50106092, 50106093, 53777437, 79854249, 90341655, 92303773, 103228861, 103922563, 103959360, 121361167, 124749627, 129309435, 134224717, 135650675, 140033717, 143178625, 162090737, 163410110, 163564285, 163848500, 172855788, 189053184, 223558168, 224442731, 226512189, 249846057, 252035498, 252212978, 252484514
|
||||
| Target and Pathway | |||||
| Target(s) | Adenosine A1 receptor | Target Info | Agonist | [2] | |
| Adenosine A2b receptor | Target Info | Agonist | [3] | ||
| Adenosine A3 receptor | Target Info | Agonist | [4] | ||
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Morphine addictionhsa04015:Rap1 signaling pathway | |||||
| Calcium signaling pathway | |||||
| Vascular smooth muscle contraction | |||||
| Alcoholism | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| RANKL Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling Pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Pathway Interaction Database | C-MYB transcription factor network | ||||
| PathWhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | ||||
| Reactome | Adenosine P1 receptors | ||||
| G alpha (i) signalling eventsR-HSA-417973:Adenosine P1 receptors | |||||
| G alpha (s) signalling events | |||||
| Surfactant metabolismR-HSA-417973:Adenosine P1 receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP80:Nucleotide GPCRs | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 423). | ||||
| REF 2 | Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors. Pharmacology. 1993;46(2):91-100. | ||||
| REF 3 | Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. Can J Physiol Pharmacol. 1980 Jun;58(6):673-91. | ||||
| REF 4 | Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J Immunol. 1996 May 1;156(9):3435-42. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.